Equity
€123,278 ▲ 79.0%
Equity rose in 2025 from €68,884 to €123,278.
SA PHARMA
Lifetime
2 annual accounts with figures on one time axispeak €71,657 (2024)
€68,746▼ 4.1%
peak €55,717 (2024)
€54,394▼ 2.4%
peak €123,278 (2025)
€123,278▲ 79.0%
€30,577▼ 9.2%
Board1 name since 2024
1 director
Documentsfilings and deeds
06-08-20266 days late
2025micro format
Equity from €68,884 to €123,278Cash from €74,205 to €109,994
Key points
from the 2025 annual accountsLiquidity
5.03 was 3.05 in 2024
Short-term debts fell from €33,659 to €30,577.
Position in the sector
80.1%
Higher solvency than 84% of companies in real estate. Sector median 31.0% · 19,823 companies.
2025 accounts filed 6 days after the deadline
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,326 companies had the same profile as SA PHARMA has now. Each dot stands for 99 companies, two years later.
95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,326 companies, not a prediction for SA PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1004498643
Incorporation
Founding capital of €14,000, 100 shares · Founder: · Appointment: (director) · published on 12-01-2024 · Gazette deed
First establishment
Waverse steenweg 1676, Auderghem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| SA PHARMA Auderghem | €153,855 | €68,746 | 80.1% | - |
| Kristien Kaelen Etterbeek | €133,270 | €87,219 | 89.1% | - |
| CATIM Dilbeek | €156,275 | €72,138 | 18.2% | - |
| COGNITIVE SEARCH Watermael-Boitsfort | €159,922 | €38,943 | 79.9% | - |
| IMMO-RENOV Molenbeek-Saint-Jean | €113,689 | €39,390 | 22.1% | - |
| JONO Dilbeek | €146,356 | €88,707 | 22.3% | - |
| Copandi VLB Tremelo | €117,014 | €74,518 | 39.7% | - |
These companies have the same main activity as SA PHARMA: buying and selling of own real estate (NACE 68110). They are comparable in size and age: total assets between €114,000 and €160,000, founded between 2023 and 2024.
Official details
Source: KBO- Status
- Active since 10-01-2024Normal situation
- Registered office
- 10 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 14 November 2026.
- Activity
- Buying and selling of own real estateNACE 68110and 5 others
- Establishment unit
- 2.354.317.1871160 Auderghem, since 10-01-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 28-01-2026
Insights on SA PHARMA
SA PHARMA has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €123,278 and a net result of €54,394.
Its solvency ranks better than 85% of 19,823 sector peers (NACE 68, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about SA PHARMA
- What is the company number of SA PHARMA?
- The company number of SA PHARMA is 1004.498.643. The VAT number is the same number with BE in front: BE 1004.498.643.
- Where is SA PHARMA based?
- The registered office is at Waverse steenweg 1676, 1160 Auderghem.Company details
- What does SA PHARMA do?
- According to the KBO register, the main activity is buying and selling of own real estate (NACE 68110).
- What is the legal form of SA PHARMA?
- SA PHARMA is a private limited company (BV).
- When was SA PHARMA founded?
- SA PHARMA was founded on 10-01-2024.
- Is SA PHARMA still active?
- Yes, SA PHARMA is an active enterprise in the KBO register.
- What is the turnover of SA PHARMA?
- The turnover in financial year 2025 is ≈ €180,000. This figure is estimated from the gross margin of €68,746 and 48 comparable companies (NACE 681). It probably lies between €93,000 and €420,000.Financials
- Is SA PHARMA profitable?
- In financial year 2025, SA PHARMA made a profit of €54,394.
- Where can I find the annual accounts of SA PHARMA?
- SA PHARMA filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of SA PHARMA due?
- SA PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.